NCT04501029Unknown2 期
A Phase Ib/II Study of Gimatecan (ST1481) for Small Cell Lung Cancer Patients Who Failed Standard Platinum-containing Chemotherapy
Lee's Pharmaceutical Limited1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2020年10月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Dose limited toxicity (DLT)
研究概览
简要总结
This phase Ib/II clinical trial studies the safety and effect of Gimatecan in small cell lung cancer patients who failed the first-line standard platinum-containing chemotherapy. The chemotherapy will be given every four weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 75 years old of either gender;
- •A histopathological or cytological diagnosis of small cell lung cancer(SCLC);
- •Recurrence or progression disease after firstline platinum-containing chemotherapy and patients intolerant or unwilling to receive standard treatment;
- •Measurable cancer lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
- •Eastern Cooperative Oncology Group(ECOG) performance status score 0-1;
- •Estimated life expectancy >4 months;
- •Taking drugs orally;
- •The function of important organs meets the following requirements:
- •white blood cell count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90g/L;
- •ALT, AST and AKP ≤ 2.5×ULN; liver metastasis: ALT、AST≤ 5.0×ULN, ALP ≤ 6.0×ULN; bone metastases ALT、AST≤ 2.5×ULN, ALP ≤ 5.0×ULN;
- •serum albumin ≥ 30g/L;
- •total bilirubin ≤ 1.5×ULN;
- •serum creatinine ≤ 1.5×ULN, creatinine clearance rate ≥60 mL/min;
- •INR ≤ 1.5, PT≤ 1.5×ULN;
- •Serum HCG negative in premenopausal women, female patients of childbearing potential and male patients with female partners of childbearing potential must be willing to avoid pregnancy;
- •Ability to understand the study and sign informed consent.
- •Key exclusion Criteria:
- •Patients who have been treated previously for SCLC with two system chemotherapy (except for targeted therapy, immunotherapy and antiangiogenic therapy);
- •Patients who have been treated previously with topotecan, Irinotecan or other topoisomerase I inhibitors;
- •Known or suspected allergy or hypersensitivity to the investigational drug gimatecan ingredients or their analogues;
- •Other anticancer therapy including any investigational agent within 28 days prior to the first dose of the investigational drug gimatecan;
- •Patients who have been treated previously with intravenous or oral drugs that affect CYP isoenzymes within 7 days prior to the first dose of the investigational drug gimatecan;
- •Brain metastasis or meningeal metastasis (except for asymptomatic patients with lesion stable more than 28 days);
- •Major surgical intervention or trauma within 28 days prior to the first dose of investigational drug administration;
- •A history of gastrointestinal disease which affects drug absorption;
- •A history of allogeneic stem cell transplantation and organ transplantation;
- •A history of interstitial lung disease or non-infectious pneumonia;
- •Patients who cannot tolerate chemotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia;
- •A history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases;
- •Presence of active hepatitis B (HBV DNA ≥ 200 IU/mL or 103 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay);
- •A history of active pulmonary tuberculosis infection within 1 year or a history of active pulmonary tuberculosis infection more than 1 year ago but without formal anti-tuberculosis treatment;
- •A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer;
- •Pregnant or lactating women.
排除标准
- 未提供
研究组 & 干预措施
Gimatecan group
Experimental
In Phase Ib study, patients will receive gimatecan at different dose level (0.4mg/m2, 0.6mg/m2,0.8mg/m2, oral, every 4 weeks) until progressive disease (PD).In Phase II study, patients will receive gimatecan at recommended phase II dose level.
干预措施: Gimatecan (Drug)
结局指标
主要结局
Dose limited toxicity (DLT)
时间窗: up to 28 days.
Phase Ib: Number of patients experienced any dose limited toxicity over the DLT period.
Recommended phase II dose (RP2D)
时间窗: up to 12 months.
Phase Ib: Determination of recommended phase II dose of escalating dose of gimatecan for the phase II part of the study.
Objective response rate (ORR)
时间窗: To evaluate objective response rate every 8 weeks after the initiation of chemotherapy, up to 24 months.
Percentage of patients with objective response assessed by best overall response (BOR) of either complete response(CR) or partial remission(PR) will be reported.
次要结局
- Progression free survival (PFS)(From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.)
- Disease control rate (DCR)(To evaluate disease control rate every 8 weeks after the initiation of chemotherapy, up to 24 months.)
- Duration of Response (DoR)(First documented CR or PR, whichever is first recorded until the first assessment of PD, assessed up to 24 months.)
- Overall survival (OS)(From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.)
- Survival rate (SR)(up to 24 months.)
- Treatment related adverse events rate(From the enrollment to 30 days later of the last chemotherapy.)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerOvarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal CancerNCT04029909Lee's Pharmaceutical Limited12
Unknown
2 期
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT04571489Lee's Pharmaceutical Limited60
Unknown
2 期
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal CancerFallopian Tube CancerPeritoneal CancerEpithelial Ovarian CancerNCT04846842Lee's Pharmaceutical Limited46
进行中（未招募）
不适用
Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimeadvanced breast cancerLevel: LLTClassification code 10006285EUCTR2004-005106-79-ESSigma Tau industrie Farmaceutiche Riunite Spa43
进行中（未招募）
不适用
A Phase II study of gimatecan (ST1481) as salvage treatment in patients with advanced or metastatic soft tissue sarcoma relapsing after anthracycline / ifosfamide - based chemotherapy regimeEUCTR2005-001951-39-ITSIGMA-TA